Search Results

Displaying Results 1-25 of 25 "'NKG'"

Aug 31, 2026, 06:30 ET NEVADA KING SECURES FOURTH DRILL RIG TO ATLANTA, PROVIDES EXPLORATION DRILLING UPDATE

VANCOUVER, BC, Aug. 31, 2026 /PRNewswire/ -- Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) ("Nevada King" or the "Company") is pleased to announce that it has secured a fourth drill rig for its 100% owned, 130km2 Atlanta

More news about: Nevada King Gold Corp.


Aug 20, 2026, 17:00 ET NEVADA KING ANNOUNCES RESULTS OF SHAREHOLDER MEETING

VANCOUVER, BC, Aug. 20, 2026 /PRNewswire/ -- Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF)  ("Nevada King" or the "Company") is pleased to announce that, at its meeting of Shareholders (the "Shareholders")

More news about: Nevada King Gold Corp.


Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results

In addition, multiple products against different targets are currently under development: CT1390B against CLL1 for AML; KJ-C2526 against NKG2DL for AML, other malignancies and senescence; KJ-C2527 against Claudin18.2 for G/GEJA, etc.; KJ-C2630 against GPC3 for hepatocellular carcinoma (HCC),

More news about: CARsgen Therapeutics


Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

differentiated Nectin-4 ADC developed in solid tumours, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).Sobi®Sobi is a global biopharma company

More news about: Swedish Orphan Biovitrum AB


Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

differentiated Nectin-4 ADC developed in solid tumours, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).Sobi®Sobi is a global biopharma company

More news about: Swedish Orphan Biovitrum AB


Jul 16, 2026, 06:30 ET NEVADA KING RECEIVES BLM APPROVAL FOR 482 ADDITIONAL DRILL SITES, ADDS THIRD DRILL RIG TO ACCELERATE FULLY FUNDED 40,000M DRILL PROGRAM

VANCOUVER, BC, July 16, 2026 /PRNewswire/ -- Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) ("Nevada King" or the "Company") is pleased to announce that it has received approval from the Bureau of Land Management

More news about: Nevada King Gold Corp.


Jul 07, 2026, 06:30 ET NEVADA KING INTERCEPTS 4.68 G/T AU OVER 7.3M AND 1.00 G/T AU OVER 26.8M NEAR SURFACE AND BOTTOMING IN MINERALIZATION AT EAST RIDGE TARGET

VANCOUVER, BC, July 7, 2026 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) ("Nevada King" or the "Company") is pleased to provide an update from its ongoing Rotary Air Blast ("RAB") reconnaissance

More news about: Nevada King Gold Corp.


Jun 26, 2026, 06:30 ET NEVADA KING GRADUATES TO THE PREMIUM OTCQX BEST MARKET, ENHANCING VISIBILITY FOR U.S. INVESTORS

VANCOUVER, BC, June 26, 2026 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) ("Nevada King" or the "Company") is pleased to announce that its common shares have been approved to begin trading today

More news about: Nevada King Gold Corp.


May 04, 2026, 17:00 ET NEVADA KING TO EFFECT SHARE CONSOLIDATION

VANCOUVER, BC, May 4, 2026 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce that, further to its news release dated April 10, 2026 and pursuant

More news about: Nevada King Gold Corp.


Apr 28, 2026, 06:30 ET NEVADA KING DOUBLES PHASE 4 DRILL PROGRAM TO 40,000 METRES, PROVIDES ASSAY RESULTS FROM SILVER PARK, AND A PROJECT WIDE PERMITTING UPDATE

VANCOUVER, BC, April 28, 2026 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to provide a comprehensive update on its exploration and permitting activities

More news about: Nevada King Gold Corp.


Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results

and THANK-u Plus™ platform. THANK-u Plus™ platform, as an enhanced version of THANK-uCAR®, was developed to address the potential impact of NKG2A expression levels on therapeutic efficacy of the allogeneic CAR T-cells.CT0596 is a BCMA-targeting allogeneic CAR T-cell product candidate deploying

More news about: CARsgen Therapeutics


Feb 03, 2026, 06:30 ET NEVADA KING EXPANDS SILVER PARK EAST MINERALIZATION WITH 350M STEP-OUT, INTERCEPTS 0.93 G/T AUEQ OVER 14.6M STARTING AT SURFACE

VANCOUVER, BC, Feb. 3, 2026 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce assay results at the Silver Park East ("SPE") target, located

More news about: Nevada King Gold Corp.


Dec 29, 2025, 06:30 ET NEVADA KING REVIEWS 2025 ACHIEVEMENTS AND 2026 EXPLORATION STRATEGY

VANCOUVER, BC, Dec. 29, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to provide a summary of its key accomplishments during 2025 and review its

More news about: Nevada King Gold Corp.


Dec 28, 2025, 19:10 ET CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

allogeneic CAR T-cell therapy targeting BCMA, developed based on CARsgen's proprietary THANK-u Plus™ platform. Through the knockout of genes such as NKG2A, TRAC, and B2M, CT0596 is designed to reduce the risk of graft-versus-host disease (GvHD) and host immune rejection. Additional gene editing further

More news about: CARsgen Therapeutics


Dec 15, 2025, 08:30 ET Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

www.leucid.com.About LEU011LEU011 is a lateral CAR-T cell therapy targeting NKG2D stress ligands, which are overexpressed on more than 80% of human tumour types and the cells within the surrounding tumour microenvironment. In addition

More news about: Leucid Bio


Dec 11, 2025, 06:30 ET NEVADA KING ANNOUNCES FULLY FUNDED 20,000M, PHASE 4 EXPLORATION PROGRAM DESIGNED TO ADVANCE MULTIPLE REGIONAL TARGETS IDENTIFIED IN PHASE 3

VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce the launch of its fully-funded Phase 4 regional exploration

More news about: Nevada King Gold Corp.


Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

dose-escalation phase who received CT0596 infusion. The median number of prior lines of therapy was 4.5 (range: 3-9). Enrollment was not restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500

More news about: CARsgen Therapeutics


Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

dose-escalation phase who received CT0596 infusion. The median number of prior lines of therapy was 4.5 (range: 3-9). Enrollment was not restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500

More news about: CARsgen Therapeutics


Dec 03, 2025, 06:00 ET NEVADA KING COMPLETES PURCHASE OF SILVER PARK PATENTED MINING CLAIMS

VANCOUVER, BC, Dec. 3, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSX-V: NKG; OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce that it has completed the purchase of the Silver Park claims after

More news about: Nevada King Gold Corp.


Nov 14, 2025, 20:00 ET NEVADA KING ENGAGES INVESTOR RELATIONS FIRM

VANCOUVER, BC, Nov. 14, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce that it has engaged Outside The Box Capital Inc. ("Outside The

More news about: Nevada King Gold Corp.


Nov 10, 2025, 06:30 ET NEVADA KING EXTENDS MINERALIZATION 150M ALONG STRIKE AT SILVER PARK EAST

VANCOUVER, BC, Nov. 10, 2025 /PRNewswire/ -- Nevada King Gold Corp. (TSX-V: NKG; OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce results for the remaining 10 holes at its Silver Park East target

More news about: Nevada King Gold Corp.


Nov 10, 2025, 03:30 ET Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours

which establish proof-of-concept for LEU011 in the treatment of solid tumours. Furthermore, they highlight LEU011's dual mechanism of action targeting NKG2D stress ligands for tumour recognition and using CXCR2 signalling to enhance T-cell infiltration into the tumour microenvironment."

More news about: Leucid Bio


Nov 03, 2025, 06:30 ET NEVADA KING ANNOUNCES JUSTIN DALEY AS VICE PRESIDENT EXPLORATION

VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce the appointment of Justin Daley as the Company's Vice President

More news about: Nevada King Gold Corp.


Oct 21, 2025, 06:30 ET NEVADA KING BEGINS DRILLING NEWLY DISCOVERED MULTI-KILOMETER VEIN CORRIDOR AT "WESTERN RIM" TARGET

VANCOUVER, BC, Oct. 21, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") has initiated drilling at the Western Rim Target, a large and newly defined multidirectional

More news about: Nevada King Gold Corp.


Oct 15, 2025, 17:00 ET NEVADA KING GRADUATES TO TIER 1 OF THE TSX VENTURE EXCHANGE

VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) ("Nevada King" or the "Company") is pleased to announce that it has received approval to graduate from Tier 2 to Tier 1

More news about: Nevada King Gold Corp.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.